![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC25A39 |
Gene summary for SLC25A39 |
![]() |
Gene information | Species | Human | Gene symbol | SLC25A39 | Gene ID | 51629 |
Gene name | solute carrier family 25 member 39 | |
Gene Alias | CGI-69 | |
Cytomap | 17q21.31 | |
Gene Type | protein-coding | GO ID | GO:0006725 | UniProtAcc | Q9BZJ4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51629 | SLC25A39 | LZE5T | Human | Esophagus | ESCC | 5.83e-03 | 5.40e-01 | 0.0514 |
51629 | SLC25A39 | LZE7T | Human | Esophagus | ESCC | 1.11e-11 | 1.08e+00 | 0.0667 |
51629 | SLC25A39 | LZE8T | Human | Esophagus | ESCC | 2.27e-03 | 3.71e-01 | 0.067 |
51629 | SLC25A39 | LZE20T | Human | Esophagus | ESCC | 4.04e-04 | 4.84e-01 | 0.0662 |
51629 | SLC25A39 | LZE22D1 | Human | Esophagus | HGIN | 1.78e-02 | 1.63e-01 | 0.0595 |
51629 | SLC25A39 | LZE22T | Human | Esophagus | ESCC | 4.28e-04 | 1.15e+00 | 0.068 |
51629 | SLC25A39 | LZE24T | Human | Esophagus | ESCC | 1.18e-36 | 1.40e+00 | 0.0596 |
51629 | SLC25A39 | LZE21T | Human | Esophagus | ESCC | 3.90e-03 | 7.32e-01 | 0.0655 |
51629 | SLC25A39 | LZE6T | Human | Esophagus | ESCC | 1.19e-06 | 6.18e-01 | 0.0845 |
51629 | SLC25A39 | P1T-E | Human | Esophagus | ESCC | 1.30e-14 | 1.10e+00 | 0.0875 |
51629 | SLC25A39 | P2T-E | Human | Esophagus | ESCC | 1.27e-43 | 1.13e+00 | 0.1177 |
51629 | SLC25A39 | P4T-E | Human | Esophagus | ESCC | 8.82e-50 | 1.59e+00 | 0.1323 |
51629 | SLC25A39 | P5T-E | Human | Esophagus | ESCC | 4.60e-88 | 2.56e+00 | 0.1327 |
51629 | SLC25A39 | P8T-E | Human | Esophagus | ESCC | 3.42e-55 | 1.22e+00 | 0.0889 |
51629 | SLC25A39 | P9T-E | Human | Esophagus | ESCC | 1.15e-31 | 1.04e+00 | 0.1131 |
51629 | SLC25A39 | P10T-E | Human | Esophagus | ESCC | 1.31e-20 | 4.46e-01 | 0.116 |
51629 | SLC25A39 | P11T-E | Human | Esophagus | ESCC | 1.38e-30 | 1.78e+00 | 0.1426 |
51629 | SLC25A39 | P12T-E | Human | Esophagus | ESCC | 3.94e-54 | 1.05e+00 | 0.1122 |
51629 | SLC25A39 | P15T-E | Human | Esophagus | ESCC | 1.33e-63 | 1.64e+00 | 0.1149 |
51629 | SLC25A39 | P16T-E | Human | Esophagus | ESCC | 6.87e-46 | 1.14e+00 | 0.1153 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00067791 | Esophagus | ESCC | porphyrin-containing compound biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
GO:00330141 | Esophagus | ESCC | tetrapyrrole biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
GO:00461482 | Esophagus | ESCC | pigment biosynthetic process | 40/8552 | 62/18723 | 2.14e-03 | 9.54e-03 | 40 |
GO:00067832 | Esophagus | ESCC | heme biosynthetic process | 20/8552 | 27/18723 | 2.61e-03 | 1.11e-02 | 20 |
GO:00330132 | Esophagus | ESCC | tetrapyrrole metabolic process | 37/8552 | 59/18723 | 6.23e-03 | 2.29e-02 | 37 |
GO:00424401 | Esophagus | ESCC | pigment metabolic process | 50/8552 | 84/18723 | 7.34e-03 | 2.64e-02 | 50 |
GO:00421681 | Esophagus | ESCC | heme metabolic process | 27/8552 | 42/18723 | 1.16e-02 | 3.90e-02 | 27 |
GO:0033013 | Liver | Cirrhotic | tetrapyrrole metabolic process | 24/4634 | 59/18723 | 5.06e-03 | 2.62e-02 | 24 |
GO:0006778 | Liver | Cirrhotic | porphyrin-containing compound metabolic process | 20/4634 | 49/18723 | 9.60e-03 | 4.35e-02 | 20 |
GO:0042168 | Liver | HCC | heme metabolic process | 30/7958 | 42/18723 | 1.40e-04 | 1.13e-03 | 30 |
GO:00330131 | Liver | HCC | tetrapyrrole metabolic process | 39/7958 | 59/18723 | 2.14e-04 | 1.63e-03 | 39 |
GO:00067781 | Liver | HCC | porphyrin-containing compound metabolic process | 33/7958 | 49/18723 | 3.86e-04 | 2.62e-03 | 33 |
GO:0042440 | Liver | HCC | pigment metabolic process | 51/7958 | 84/18723 | 5.74e-04 | 3.65e-03 | 51 |
GO:0006783 | Liver | HCC | heme biosynthetic process | 19/7958 | 27/18723 | 3.18e-03 | 1.47e-02 | 19 |
GO:0006779 | Liver | HCC | porphyrin-containing compound biosynthetic process | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
GO:0033014 | Liver | HCC | tetrapyrrole biosynthetic process | 21/7958 | 31/18723 | 4.01e-03 | 1.76e-02 | 21 |
GO:0046148 | Liver | HCC | pigment biosynthetic process | 37/7958 | 62/18723 | 4.73e-03 | 2.02e-02 | 37 |
GO:00461481 | Oral cavity | OSCC | pigment biosynthetic process | 36/7305 | 62/18723 | 1.82e-03 | 8.57e-03 | 36 |
GO:00067831 | Oral cavity | OSCC | heme biosynthetic process | 17/7305 | 27/18723 | 1.01e-02 | 3.49e-02 | 17 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A39 | SNV | Missense_Mutation | novel | c.512N>G | p.Ala171Gly | p.A171G | Q9BZJ4 | protein_coding | deleterious(0.02) | probably_damaging(0.992) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SLC25A39 | SNV | Missense_Mutation | c.788N>T | p.Gly263Val | p.G263V | Q9BZJ4 | protein_coding | deleterious(0.03) | benign(0.41) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
SLC25A39 | insertion | Frame_Shift_Ins | novel | c.120_121insCTTTGGGAGGCTGAGGTGGGTGGATCACCTGA | p.Ser41LeufsTer21 | p.S41Lfs*21 | Q9BZJ4 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
SLC25A39 | SNV | Missense_Mutation | rs748101051 | c.792N>G | p.Ile264Met | p.I264M | Q9BZJ4 | protein_coding | deleterious(0.05) | benign(0.071) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC25A39 | SNV | Missense_Mutation | rs757102633 | c.112N>T | p.Arg38Cys | p.R38C | Q9BZJ4 | protein_coding | deleterious(0) | possibly_damaging(0.693) | TCGA-IR-A3LC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | Complete Response |
SLC25A39 | SNV | Missense_Mutation | rs746042795 | c.832G>A | p.Val278Met | p.V278M | Q9BZJ4 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
SLC25A39 | SNV | Missense_Mutation | rs745986185 | c.638N>A | p.Arg213His | p.R213H | Q9BZJ4 | protein_coding | tolerated(0.25) | probably_damaging(0.959) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A39 | SNV | Missense_Mutation | c.575A>G | p.Gln192Arg | p.Q192R | Q9BZJ4 | protein_coding | tolerated(1) | benign(0.006) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SLC25A39 | SNV | Missense_Mutation | rs139586541 | c.848N>A | p.Arg283His | p.R283H | Q9BZJ4 | protein_coding | deleterious(0) | possibly_damaging(0.634) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A39 | SNV | Missense_Mutation | c.206N>G | p.Gln69Arg | p.Q69R | Q9BZJ4 | protein_coding | tolerated(0.48) | benign(0) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |